| Literature DB >> 29510124 |
Nurgul Aytan1, Ji-Kyung Choi2, Isabel Carreras3, Leah Crabtree4, Brian Nguyen5, Margaret Lehar6, Jan Krzysztof Blusztajn7, Bruce G Jenkins8, Alpaslan Dedeoglu9.
Abstract
Interest in brain-derived neurotrophic factor (BDNF) was greatly enhanced when it was recognized that its expression is reduced in neurodegenerative disorders, especially in Alzheimer's disease (AD). BDNF signaling through the TrkB receptor has a central role in promoting synaptic transmission, synaptogenesis, and facilitating synaptic plasticity making the BDNF-TrkB signaling pathway an attractive candidate for targeted therapies. Here we investigated the early effect of the small molecule TrkB agonist, 7,8 dihydroxyflavone (7,8-DHF), on AD-related pathology, dendritic arborization, synaptic density, and neurochemical changes in the 5xFAD mouse model of AD. We treated 5xFAD mice with 7,8-DHF for 2 months beginning at 1 month of age. We found that, in this model of AD, 7,8-DHF treatment decreased cortical Aβ plaque deposition and protected cortical neurons against reduced dendritic arbor complexity but had no significant impact on the density of dendritic spines. In addition 7,8-DHF treatment protected against hippocampal increase in the level of choline-containing compounds and glutamate loss, but had no significant impact on hippocampal neurogenesis.Entities:
Keywords: 7,8-Dihydroxyflavone; Alzheimer's disease; Brain-derived neurotrophic factor (BDNF); Choline
Mesh:
Substances:
Year: 2018 PMID: 29510124 PMCID: PMC5971844 DOI: 10.1016/j.ejphar.2018.02.045
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432